Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Adagene (NASDAQ:ADAG) Stock Retreats in a Quiet Week After Trial Enrollment Milestone

Adagene is a clinical-stage company developing masked antibody therapies using its SAFEbody technology. Its lead program is muzastotug, which it is testing in combination with Merck (NYSE:MRK)'s Keytruda, or pembrolizumab, in microsatellite stable colorectal cancer, a form of the disease that has historically responded …

Nitish Kishor | 16 November 2026

Aquestive Therapeutics (NASDAQ:AQST) Stock Climbs as Anaphylm Decision Looms

The company published no press release, regulatory update or analyst action dated November 12 or 13. Its latest substantive news was the third-quarter 2026 report, covered in a November 4Earningsanalysis, more than a week before this session.

Nitish Kishor | 16 November 2026

Aspen Neuroscience (NASDAQ:ASPE) Stock Sinks Further Under Its IPO Price Two Weeks After Listing

The company published no announcement for the session, so the fall came against the stock's short trading history and Friday's weak market backdrop.

Nitish Kishor | 16 November 2026

Candel Therapeutics (NASDAQ:CADL) Drops Sharply Amid Biotech Volatility

Clinical-stage biotech names like Candel are inherently binary and sentiment-driven. Their value rests on expectations about programs still working their way through development and toward regulatory milestones, and the company is advancing toward a year-end biologics license application filing for a prostate cancer therapy. …

Nitish Kishor | 16 November 2026

CVS Spent Two Decades Building an Empire. Now It’s Taking It Apart

CVS Health (NYSE:CVS) had a good quarter and a bad day. On November 4th it reported adjustedEarningsof $2.09 a share, against the $1.65 analysts expected. It raised its 2026 forecast to at least $8.20 and guided to at least $8.65 for 2027, ahead of …

Nitish Kishor | 15 November 2026

Why Did LifeMD (NASDAQ:LFMD) Jump 39.27% Despite a Revenue Guidance Cut?

Key HighlightsLifeMD (NASDAQ:LFMD) traded at USD 2.31 intraday on November 13, 2026, up 39.27%, on about 2.69 million shares, more than three times its averageVolumeof about 784,000.Third quarterRevenuewas USD 44.6 million, down about 7% and below guidance, and full year 2026 revenue guidance was …

Vinay Lochav | 13 November 2026

Why Is DataMEDS AI (NASDAQ:MEDS) Moving After a Q3 Profit Built on Debt Relief?

Key HighlightsDataMEDS AI (NASDAQ:MEDS) traded at USD 0.92 intraday on November 13, 2026, up 6.24%, with aMarket Valueof about USD 4.74 million, near its 52-week low of USD 0.82.The company reported a third quarter net operating profit of about USD 10.5 million against a …

Vinay Lochav | 13 November 2026

Why Did Prime Medicine (NASDAQ:PRME) Rise 8.49% After Extending Its Runway Through 2027?

Key HighlightsPrime Medicine (NASDAQ:PRME) traded at USD 4.22 intraday on November 13, 2026, up 8.49%, giving aMarket Valueof about USD 766 million.Third quarterRevenuerose to about USD 4.2 million from about USD 1.2 million, and the net loss narrowed to USD 39.0 million, or USD …

Vinay Lochav | 13 November 2026

Can a Medicare Rate Lift Lucid Diagnostics (NASDAQ:LUCD) From USD 0.45?

Key HighlightsLucid Diagnostics (NASDAQ:LUCD) traded at USD 0.45 intraday on November 13, 2026, up 8.14%, with aMarket Valueof about USD 85.9 million.Medicare now pays a national rate of USD 1,938.01 per EsoGuard test from October 2026, and October testVolumeexceeded 1,800.Third quarterRevenuewas flat at about …

Vinay Lochav | 13 November 2026

Why Did Cerenome (NASDAQ:CNSY) Jump 42.76% as Brain Cancer Data Hit the Spotlight?

Key HighlightsCerenome (NASDAQ:CNSY) traded at USD 1.10 intraday on November 13, 2026, up 42.76%, on about 1.37 million shares, roughly twice its average volume, with aMarket Valueof about USD 8.24 million.Interim results from the first ten patients in a multidose trial of REYOBIQ in …

Vinay Lochav | 13 November 2026
Support

Hi! How can we help you today?

Loading…